search
Back to results

Estrogen and Graft Atherosclerosis Research Trial (EAGER)

Primary Purpose

Cardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
hormone replacement therapy
estrogens
medroxyprogesterone
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiovascular Diseases

Eligibility Criteria

45 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Postmenopausal women who had undergone coronary artery bypass graft.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    October 27, 1999
    Last Updated
    February 17, 2016
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00000605
    Brief Title
    Estrogen and Graft Atherosclerosis Research Trial (EAGER)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2005
    Overall Recruitment Status
    Completed
    Study Start Date
    August 1996 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    July 2002 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To determine if postmenopausal hormone replacement therapy in women following coronary bypass surgery would reduce the occurrence of graft occlusion and delay the development of graft atherosclerosis.
    Detailed Description
    BACKGROUND: Coronary atherosclerosis is a major cause of death in women in the United States. Although coronary artery bypass surgery decreases symptomatic and clinical evidence of ischemia, it does not alter the underlying process. Patients may present several years later with recurrent symptoms that may be a result of occlusion of saphenous vein grafts, development of atherosclerotic disease in vein grafts, or progression of underlying disease. Any intervention that can reduce the rate of progression of coronary atherosclerosis following bypass surgery would provide significant benefit for women following bypass surgery and possibly for other women with atherosclerotic disease. Observational studies suggest that postmenopausal estrogen replacement therapy is associated with a reduction in cardiac morbidity. DESIGN NARRATIVE: The study was a randomized, double-blind, controlled trial. Subjects were randomized to conjugated estrogen with daily medroxyprogesterone or placebo within two weeks of bypass surgery. Graft occlusion and development of vein graft atherosclerosis were measured by comparing quantitative coronary angiographic and vascular ultrasonic assessment of disease severity and extent performed at six months and three and a half years after randomization. The primary outcome variables included the occurrence of graft occlusion at six months and the change in severity and extent of atherosclerosis in the saphenous vein grafts over three years. The trial determined the influence of hormone replacement therapy on the primary outcome variables. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cardiovascular Diseases, Coronary Arteriosclerosis, Coronary Disease, Heart Diseases, Myocardial Ischemia, Postmenopause

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Masking
    Double
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    hormone replacement therapy
    Intervention Type
    Drug
    Intervention Name(s)
    estrogens
    Intervention Type
    Drug
    Intervention Name(s)
    medroxyprogesterone

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Postmenopausal women who had undergone coronary artery bypass graft.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Pamela Ouyang
    Organizational Affiliation
    Johns Hopkins University

    12. IPD Sharing Statement

    Learn more about this trial

    Estrogen and Graft Atherosclerosis Research Trial (EAGER)

    We'll reach out to this number within 24 hrs